Purpose: Diabetic patients had erectile dysfunction at an earlier age and with greater frequency than nondiabetic males, with prevalence rates ranging from 20% to 75%. The aim of the work is to study the efficacy and safety of different doses of vardenafil in patients with long-standing type II DM on Erectile Dysfunction (ED), testosterone level, and partner satisfaction.
Methods: A randomized clinical investigation was undertaken spanning the period from October 2021 to October 2022 on patients with long-standing type II DM who were diagnosed with ED and were randomized into 4 groups to receive vardenafil, 5 mg once, 5 mg twice, 10 mg once, and 10 mg twice, respectively. The International Index of Erectile Function (IIEF) self-completed questionnaire was used to measure erectile dysfunction, the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire was used to measure partner satisfaction, and testosterone levels were taken both before and after vardenafil was administered.
Results: Of 102 patients, 26 patients received 5 mg once daily, 25 patients received 5 mg twice daily, 27 patients received 10 mg once daily and 24 patients received 10 mg twice daily. The mean age was 55.45 ± 8.142 years, ranging from 40 to 65 years, HbA1c mean was 8.8% ± 1.5. There was a statistically significant difference regarding EDITS and IIEF-15 scores among patients who received 10 mg once and 5 mg twice, p = 0.001. Testosterone levels were elevated in all doses, especially for higher doses of vardenafil.
Conclusion: Vardenafil with doses of 10 mg once or 5 mg twice is an effective and valid option for long-standing type II diabetic patients with ED.
Keywords: Vardenafil; diabetes; erectile dysfunction.
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.